Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

Peer Review reports

Original Submission
6 Jan 2020	Submitted	Original manuscript
30 Mar 2020	Reviewed	Reviewer Report - Mehmet Akce
13 Apr 2020	Reviewed	Reviewer Report - Hassan Hatoum
17 Apr 2020	Author responded	Author comments - Ghulam Rehman Mohyuddin
4 May 2020	Reviewed	Reviewer Report - Mehmet Akce
6 May 2020	Reviewed	Reviewer Report - Hassan Hatoum
8 May 2020	Author responded	Author comments - Ghulam Rehman Mohyuddin
Resubmission - Version 2
17 Apr 2020	Submitted	Manuscript version 2
Publishing
11 May 2020	Editorially accepted
3 Jun 2020	Article published	10.1186/s12885-020-06948-5

Back to article page